JP2017535246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535246A5 JP2017535246A5 JP2017512808A JP2017512808A JP2017535246A5 JP 2017535246 A5 JP2017535246 A5 JP 2017535246A5 JP 2017512808 A JP2017512808 A JP 2017512808A JP 2017512808 A JP2017512808 A JP 2017512808A JP 2017535246 A5 JP2017535246 A5 JP 2017535246A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- set forth
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical group 0.000 claims 114
- 239000000611 antibody drug conjugate Substances 0.000 claims 17
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 229940127089 cytotoxic agent Drugs 0.000 claims 7
- 239000002254 cytotoxic agent Substances 0.000 claims 7
- 231100000599 cytotoxic agent Toxicity 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 101000798109 Homo sapiens Melanotransferrin Proteins 0.000 claims 6
- 102100032239 Melanotransferrin Human genes 0.000 claims 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 201000000849 skin cancer Diseases 0.000 claims 5
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 4
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 4
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 claims 4
- 210000005102 tumor initiating cell Anatomy 0.000 claims 4
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 2
- 108010027164 Amanitins Proteins 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 101100261262 Homo sapiens MELTF gene Proteins 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 2
- CIORWBWIBBPXCG-JZTFPUPKSA-N amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2CC(O)C[C@H]2C(=O)N[C@@H](C(C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-JZTFPUPKSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 108010044540 auristatin Proteins 0.000 claims 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 2
- 229930195731 calicheamicin Natural products 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical group CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 2
- 229930188854 dolastatin Natural products 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims 2
- 229960005501 duocarmycin Drugs 0.000 claims 2
- 229930184221 duocarmycin Natural products 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- -1 maytansinoid Natural products 0.000 claims 2
- 208000021039 metastatic melanoma Diseases 0.000 claims 2
- 229940125645 monoclonal antibody drug Drugs 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 230000004611 cancer cell death Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 229960002433 cysteine Drugs 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000004237 preparative chromatography Methods 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462046610P | 2014-09-05 | 2014-09-05 | |
| US62/046,610 | 2014-09-05 | ||
| US201562203836P | 2015-08-11 | 2015-08-11 | |
| US62/203,836 | 2015-08-11 | ||
| PCT/US2015/048659 WO2016037119A1 (en) | 2014-09-05 | 2015-09-04 | Novel anti-mfi2 antibodies and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017535246A JP2017535246A (ja) | 2017-11-30 |
| JP2017535246A5 true JP2017535246A5 (esLanguage) | 2019-04-25 |
Family
ID=55440418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512808A Pending JP2017535246A (ja) | 2014-09-05 | 2015-09-04 | 新規の抗ｍｆｉ２抗体および使用方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10428156B2 (esLanguage) |
| EP (1) | EP3189079A4 (esLanguage) |
| JP (1) | JP2017535246A (esLanguage) |
| KR (1) | KR20170045351A (esLanguage) |
| CN (1) | CN107001454A (esLanguage) |
| AU (1) | AU2015311743A1 (esLanguage) |
| BR (1) | BR112017004444A2 (esLanguage) |
| CA (1) | CA2959705A1 (esLanguage) |
| CL (2) | CL2017000506A1 (esLanguage) |
| CO (1) | CO2017003005A2 (esLanguage) |
| CR (1) | CR20170117A (esLanguage) |
| DO (1) | DOP2017000052A (esLanguage) |
| EA (1) | EA201790529A1 (esLanguage) |
| IL (1) | IL250825A0 (esLanguage) |
| MA (1) | MA40612A (esLanguage) |
| MX (1) | MX2017002862A (esLanguage) |
| PE (1) | PE20170776A1 (esLanguage) |
| PH (1) | PH12017500406A1 (esLanguage) |
| SG (1) | SG11201701650PA (esLanguage) |
| TW (1) | TW201617368A (esLanguage) |
| WO (1) | WO2016037119A1 (esLanguage) |
| ZA (1) | ZA201701674B (esLanguage) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3020864A1 (en) | 2016-04-15 | 2017-10-19 | Macrogenics, Inc. | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof |
| WO2019167874A1 (ja) * | 2018-02-27 | 2019-09-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ａｐｏａ４に対するモノクローナル抗体、免疫学的測定方法及び測定用キット |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| US12134650B2 (en) * | 2018-07-26 | 2024-11-05 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer |
| CN113498350A (zh) * | 2018-12-21 | 2021-10-12 | 萨普雷米科技有限公司 | 皂苷缀合物 |
| CN109709340B (zh) * | 2018-12-29 | 2022-02-11 | 江苏众红生物工程创药研究院有限公司 | 人中性粒细胞明胶酶相关脂质运载蛋白定量检测卡及其临床应用 |
| WO2020150282A1 (en) * | 2019-01-18 | 2020-07-23 | Askgene Pharma Inc. | Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis |
| AU2020219732A1 (en) * | 2019-02-05 | 2021-08-05 | Seagen Inc. | Anti-CD228 antibodies and antibody-drug conjugates |
| CN114401741A (zh) | 2019-07-11 | 2022-04-26 | 拓维创新生物科技(香港)有限公司 | 干扰胸腺基质淋巴细胞生成素(tslp)受体信号传导的药剂 |
| GB201913594D0 (en) * | 2019-09-20 | 2019-11-06 | Univ Birmingham | Epigenetic profiling method |
| WO2021225954A1 (en) * | 2020-05-04 | 2021-11-11 | The Regents Of The University Of California | Inhibiting anti-enpp1 antibodies |
| CN111909933B (zh) * | 2020-06-29 | 2021-07-02 | 浙江大学 | 靶向细胞表面抗原mfi2蛋白的核酸适配体及应用 |
| CN116568337A (zh) * | 2020-08-04 | 2023-08-08 | 思进股份有限公司 | 抗cd228抗体和抗体-药物缀合物 |
| WO2022187050A1 (en) * | 2021-03-01 | 2022-09-09 | BioLegend, Inc. | Anti-cd117 agents and compositions and methods for making and using the same |
| CN116925216B (zh) * | 2022-04-11 | 2024-09-24 | 东莞市朋志生物科技有限公司 | 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒 |
| KR20250069943A (ko) * | 2022-09-21 | 2025-05-20 | 씨젠 인크. | Cd228과 결합하는 항체 |
| WO2025025731A1 (zh) * | 2023-07-28 | 2025-02-06 | 山东博安生物技术股份有限公司 | 一种适用于免疫组化检测cd228的诊断抗体 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| USRE38008E1 (en) | 1986-10-09 | 2003-02-25 | Neorx Corporation | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5191066A (en) | 1990-12-07 | 1993-03-02 | Abbott Laboratories | Site-specific conjugation of immunoglobulins and detectable labels |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| US6146850A (en) | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5981194A (en) | 1992-07-10 | 1999-11-09 | University Of British Columbia | Use of p97 and iron binding proteins as diagnostic and therapeutic agents |
| ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| DE69739909D1 (de) | 1996-03-26 | 2010-07-29 | Michael S Kopreski | Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden |
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
| AU2559799A (en) | 1998-01-22 | 1999-08-09 | Genentech Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same |
| EP1413582B1 (en) | 1998-08-27 | 2006-03-15 | Spirogen Limited | Dimeric pyrrolobenzodiazepines |
| MX353234B (es) | 1999-01-15 | 2018-01-08 | Genentech Inc | Variantes de polipeptidos con función efectora alterada. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP4414023B2 (ja) * | 1999-08-05 | 2010-02-10 | オリエンタル酵母工業株式会社 | 関節炎関連メラノトランスフェリンの測定方法および試薬 |
| US20040055022A1 (en) | 2000-02-08 | 2004-03-18 | Nick Cheng | Compositions and methods for screening therapeutic agents |
| KR20020007432A (ko) | 2000-07-13 | 2002-01-29 | 박현석 | 멜라노트랜스페린에 대한 단클론 항체를 유효성분으로포함하는 알츠하이머병의 진단시약 |
| DE60143544D1 (de) | 2000-12-12 | 2011-01-05 | Medimmune Llc | Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung |
| US6362331B1 (en) | 2001-03-30 | 2002-03-26 | Council Of Scientific And Industrial Research | Process for the preparation of antitumor agents |
| EP1256354A1 (en) | 2001-05-11 | 2002-11-13 | Schering Corporation | Methods for treating cancer |
| TW200303759A (en) | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| ATE541857T1 (de) | 2002-09-27 | 2012-02-15 | Xencor Inc | Optimierte fc-varianten und herstellungsverfahren dafür |
| EP1578447A4 (en) | 2002-10-31 | 2009-06-03 | Genentech Inc | METHOD AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION |
| EP1419786A1 (en) | 2002-11-13 | 2004-05-19 | Bracco Imaging S.p.A. | Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof |
| GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| JP4884224B2 (ja) | 2003-05-09 | 2012-02-29 | ディアデクサス インコーポレーテッド | Ｏｖｒ１１０抗体組成物および使用方法 |
| CA2525243C (en) | 2003-05-09 | 2014-05-27 | Transfert Plus | Use of melanotransferrin (p97) for regulating plasminogen activation and cell migration |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| EP1663306A2 (en) | 2003-09-05 | 2006-06-07 | Genentech, Inc. | Antibodies with altered effector functions |
| GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
| US7807392B1 (en) | 2003-09-15 | 2010-10-05 | Celera Corporation | Lung disease targets and uses thereof |
| GB0404577D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| JP4909258B2 (ja) | 2004-03-01 | 2012-04-04 | スピロゲン リミティッド | Ｃ２置換ピロロベンゾジアゼピン類を調製するための主要な中間体としての１１−ヒドロキシ−５Ｈ−ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−５−オン誘導体 |
| CA2558399C (en) | 2004-03-02 | 2015-05-19 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| US7189710B2 (en) | 2004-03-30 | 2007-03-13 | Council Of Scientific And Industrial Research | C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers |
| FR2869231B1 (fr) | 2004-04-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| JP2008521828A (ja) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス， インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
| JP5255435B2 (ja) | 2005-04-26 | 2013-08-07 | メディミューン，エルエルシー | ヒンジドメイン操作による抗体エフェクター機能の調節 |
| DK1874821T3 (da) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| US7521195B1 (en) | 2005-07-21 | 2009-04-21 | Celera Corporation | Lung disease targets and uses thereof |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| PT1813614E (pt) | 2006-01-25 | 2012-01-09 | Sanofi Sa | Agentes citotóxicos compreendendo novos derivados de tomaimicina |
| BRPI0711249A2 (pt) | 2006-05-30 | 2012-03-13 | Genentech, Inc. | Anticorpos, polinucleotídeos, vetores, células hospedeira, métodos para fabricar um anticorpo, para detectar a presença de cd2 em uma amostra biológica, para tratar uma disfunção proliferativa de células b, para inibir proliferaçõa de células b, para tratar câncer, para fabricar um composto conjugado anti-corpo-droga. imunoconjugados,composições farmacêuticas, formulações farmacêuticas, conjugado anticorpo-droga, compostos conjugados anti-corpo-droga, teste para detectar células b e artigo de fabricação |
| AU2007258744A1 (en) | 2006-06-06 | 2007-12-21 | University Of Tennessee Research Foundation | Compositions enriched in neoplastic stem cells and methods comprising same |
| US20080220448A1 (en) | 2006-09-01 | 2008-09-11 | Blincko Stuart J | Antigenic protein conjugates and process for preparing same |
| JP5550905B2 (ja) | 2006-09-07 | 2014-07-16 | スコット アンド ホワイト ヘルスケア | ジフテリア毒素−インターロイキン−３コンジュゲートに基づく方法及び組成物 |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| AU2008207945A1 (en) | 2007-01-22 | 2008-07-31 | Macrogenics West, Inc. | Human cancer stem cells |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| AU2008296386A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of IGF-1R |
| US20100226925A1 (en) | 2007-09-14 | 2010-09-09 | Amgen Inc. | Homogeneous Antibody Populations |
| US20090155255A1 (en) | 2007-09-27 | 2009-06-18 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| AU2009205995B2 (en) | 2008-01-18 | 2014-04-03 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
| US20100162416A1 (en) | 2008-09-29 | 2010-06-24 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| EP3674317B1 (en) | 2009-03-19 | 2024-12-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| UA115221C2 (uk) | 2010-02-21 | 2017-10-10 | БАЄР ХЕЛСКЕР ЛЛСі | Спосіб активації та кон'югації фактора коагуляції |
| JP5889181B2 (ja) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI540136B (zh) | 2010-04-15 | 2016-07-01 | 梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
| GB201006340D0 (en) | 2010-04-15 | 2010-06-02 | Spirogen Ltd | Synthesis method and intermediates |
| BR112012026410B8 (pt) | 2010-04-15 | 2023-01-31 | Spirogen Dev Sarl | Composto e conjugado de pirrolobenzodiazepinas e usos dos mesmos |
| CN107019804A (zh) * | 2010-04-15 | 2017-08-08 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| CN103068406B (zh) | 2010-06-08 | 2017-06-30 | 基因泰克公司 | 半胱氨酸改造的抗体和偶联物 |
| WO2012031280A2 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| CN105424942B (zh) | 2010-09-17 | 2017-07-18 | 国立研究开发法人产业技术综合研究所 | 肺癌鉴定标志物 |
| EP2638066A4 (en) | 2010-11-09 | 2015-06-03 | Medimmune Llc | ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION |
| WO2012078761A2 (en) | 2010-12-09 | 2012-06-14 | Bayer Healthcare Llc | Dimeric molecular complexes with free cysteine residues and conjugates thereof |
| MY164647A (en) | 2011-03-02 | 2018-01-30 | Roche Glycart Ag | Cea antibodies |
| EP3088005B1 (en) * | 2011-07-05 | 2019-01-02 | biOasis Technologies Inc | P97-antibody conjugates |
| DK2739649T3 (en) | 2011-08-05 | 2018-01-08 | Bioasis Technologies Inc | P97 FRAGMENTS WITH TRANSFER ACTIVITY |
| CN103998463A (zh) | 2011-10-19 | 2014-08-20 | 瑟瑞技术公司 | 衍生自黑素转铁蛋白的肽化合物和其用途 |
| KR20110136776A (ko) * | 2011-12-12 | 2011-12-21 | 경북대학교 산학협력단 | 당뇨병성 신증 진단용 바이오마커 및 이의 동정방법 |
| RS60499B1 (sr) | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| WO2013093809A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| PE20150091A1 (es) * | 2012-02-24 | 2015-02-16 | Stem Centrx Inc | Anticuerpos anti-sez6 y metodos de empleo |
| AU2013229786B2 (en) * | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| US9475824B2 (en) * | 2012-07-20 | 2016-10-25 | Cleave Biosciences, Inc. | Fused pyrimidines as inhibitors of p97 complex |
| JP6273205B2 (ja) | 2012-10-05 | 2018-01-31 | 協和発酵キリン株式会社 | ヘテロダイマータンパク質組成物 |
| SMT202100265T1 (it) | 2012-10-12 | 2021-07-12 | Medimmune Ltd | Pirrolobenzodiazepine e loro coniugati |
| EP2839860B1 (en) | 2012-10-12 | 2019-05-01 | MedImmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| DK2953976T3 (da) | 2013-02-08 | 2021-06-21 | Novartis Ag | Specifikke modificeringssteder i antistoffer til fremstilling af immunkonjugater |
| SMT201900339T1 (it) | 2013-02-22 | 2019-07-11 | Medimmune Ltd | Coniugati anticorpo anti-dll3/pbd e loro usi |
| AU2014243816B2 (en) | 2013-03-13 | 2019-01-31 | Bioasis Technologies Inc. | Fragments of p97 and uses thereof |
| EP3003387A1 (en) | 2013-06-04 | 2016-04-13 | Cytomx Therapeutics Inc. | Compositions and methods for conjugating activatable antibodies |
| MX2015016963A (es) | 2013-06-10 | 2016-08-08 | Dana Farber Cancer Inst Inc | Metodos y composiciones para reducir la inmunosupresion por celulas de tumor. |
| AU2014293011A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene |
| WO2015031698A1 (en) | 2013-08-28 | 2015-03-05 | Stem Centrx, Inc. | Site-specific antibody conjugation methods and compositions |
| AU2014312190A1 (en) | 2013-08-28 | 2016-02-18 | Bioasis Technologies Inc. | CNS-targeted conjugates of antibodies |
| WO2015035606A1 (en) | 2013-09-13 | 2015-03-19 | Beigene, Ltd. | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| CN106456725B9 (zh) | 2014-02-11 | 2022-08-09 | 西雅图基因公司 | 蛋白质的选择性还原 |
| KR20170008202A (ko) | 2014-02-21 | 2017-01-23 | 애브비 스템센트알엑스 엘엘씨 | 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체 |
| EP3209334A2 (en) | 2014-10-20 | 2017-08-30 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
-
2015
- 2015-09-03 TW TW104129184A patent/TW201617368A/zh unknown
- 2015-09-04 WO PCT/US2015/048659 patent/WO2016037119A1/en not_active Ceased
- 2015-09-04 AU AU2015311743A patent/AU2015311743A1/en not_active Abandoned
- 2015-09-04 SG SG11201701650PA patent/SG11201701650PA/en unknown
- 2015-09-04 EP EP15837897.6A patent/EP3189079A4/en not_active Withdrawn
- 2015-09-04 KR KR1020177009300A patent/KR20170045351A/ko not_active Withdrawn
- 2015-09-04 CA CA2959705A patent/CA2959705A1/en not_active Abandoned
- 2015-09-04 BR BR112017004444-7A patent/BR112017004444A2/en not_active Application Discontinuation
- 2015-09-04 US US15/508,836 patent/US10428156B2/en not_active Expired - Fee Related
- 2015-09-04 PE PE2017000403A patent/PE20170776A1/es unknown
- 2015-09-04 EA EA201790529A patent/EA201790529A1/ru unknown
- 2015-09-04 JP JP2017512808A patent/JP2017535246A/ja active Pending
- 2015-09-04 MX MX2017002862A patent/MX2017002862A/es unknown
- 2015-09-04 CN CN201580060426.9A patent/CN107001454A/zh active Pending
- 2015-09-04 CR CR20170117A patent/CR20170117A/es unknown
- 2015-09-04 MA MA040612A patent/MA40612A/fr unknown
-
2017
- 2017-02-27 IL IL250825A patent/IL250825A0/en unknown
- 2017-03-02 DO DO2017000052A patent/DOP2017000052A/es unknown
- 2017-03-03 CL CL2017000506A patent/CL2017000506A1/es unknown
- 2017-03-03 PH PH12017500406A patent/PH12017500406A1/en unknown
- 2017-03-08 ZA ZA2017/01674A patent/ZA201701674B/en unknown
- 2017-03-28 CO CONC2017/0003005A patent/CO2017003005A2/es unknown
-
2018
- 2018-06-22 CL CL2018001722A patent/CL2018001722A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535246A5 (esLanguage) | ||
| US9353182B2 (en) | Anti-DLL3 antibodies | |
| ES2763548T3 (es) | Anticuerpos anti-TIM3 y procedimientos de uso | |
| JP2018127469A5 (esLanguage) | ||
| JP2016531915A5 (esLanguage) | ||
| JP2016531914A5 (esLanguage) | ||
| US20190201542A1 (en) | Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transition | |
| JP7657213B2 (ja) | 抗メソテリンエリブリン抗体－薬物コンジュゲート及び使用方法 | |
| JP2019532056A5 (esLanguage) | ||
| KR20160070191A (ko) | 신규한 항-클라우딘 항체 및 사용 방법 | |
| JP2018529656A (ja) | 抗ｄｌｌ３抗体薬物コンジュゲートおよび使用方法 | |
| KR20160097336A (ko) | 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법 | |
| JP2016536020A5 (esLanguage) | ||
| CN110494448B (zh) | 包含抗-ly75抗体的医药组合 | |
| KR20160047567A (ko) | 조작된 항-dll3 접합체 및 사용 방법 | |
| KR20180088445A (ko) | 신규한 항-클라우딘 항체 및 사용 방법 | |
| ES3007557T3 (en) | Anti-edb antibodies and antibody-drug conjugates | |
| JP2020502271A (ja) | 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法 | |
| JP2015509948A5 (esLanguage) | ||
| KR20170045351A (ko) | 신규한 항-mfi2 항체 및 사용 방법 | |
| JP7578289B2 (ja) | Ｍｕｃ１８に特異的な抗体 | |
| AU2016355206A1 (en) | Novel anti-EMR2 antibodies and methods of use | |
| JP2019511199A (ja) | 新規の抗ｕｐｋ１ｂ抗体及び使用方法 | |
| AU2017261369A1 (en) | Novel anti-TNFRSF21 antibodies and methods of use | |
| JPWO2020143749A5 (esLanguage) |